{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T14:18:05Z","timestamp":1795097885974,"version":"4.10.3"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001349","name":"MOH | National Medical Research Council","doi-asserted-by":"publisher","award":["Young Investigator Research Grant (16may021)"],"award-info":[{"award-number":["Young Investigator Research Grant (16may021)"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"MOH | National Medical Research Council","doi-asserted-by":"publisher","award":["CIRG17may014"],"award-info":[{"award-number":["CIRG17may014"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Despite their limitations, unfractionated heparin (UFH) and bivalirudin remain standard-of-care parenteral anticoagulants for percutaneous coronary intervention (PCI). We discovered novel direct thrombin inhibitors (DTIs) from tick salivary transcriptomes and optimised their pharmacologic activity. The most potent, ultravariegin, inhibits thrombin with a\n                    <jats:italic>K<\/jats:italic>\n                    <jats:sub>\n                      <jats:italic>i<\/jats:italic>\n                    <\/jats:sub>\n                    of 4.0\u2009pM, 445-fold better than bivalirudin. Unexpectedly, despite their greater antithrombotic effect, variegin\/ultravariegin demonstrated less bleeding, achieving a 3-to-7-fold wider therapeutic index in rodent thrombosis and bleeding models. When used in combination with aspirin and ticagrelor in a porcine model, variegin\/ultravariegin reduced stent thrombosis compared with antiplatelet therapy alone but achieved a 5-to-7-fold lower bleeding time than UFH\/bivalirudin. Moreover, two antibodies screened from a na\u00efve human antibody library effectively reversed the anticoagulant activity of ultravariegin, demonstrating proof-of-principle for antidote reversal. Variegin and ultravariegin are promising translational candidates for next-generation DTIs that may reduce peri-PCI bleeding in the presence of antiplatelet therapy.\n                  <\/jats:p>","DOI":"10.1038\/s41467-021-27275-8","type":"journal-article","created":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T06:08:02Z","timestamp":1637820482000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy and safety of next-generation tick transcriptome-derived direct thrombin inhibitors"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0002-4603","authenticated-orcid":false,"given":"Cho Yeow","family":"Koh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norrapat","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina Y. C.","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7587-1420","authenticated-orcid":false,"given":"Aaron Wei Liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fathiah S.","family":"Amran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther Jia En","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janaki Krishnamoorthy","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Croft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Ibrahim Bin","family":"Mazlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Lin","family":"Chee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eng-Soo","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dougald M.","family":"Monroe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7123-0100","authenticated-orcid":false,"given":"Maureane","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard C.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique P. V.","family":"de Kleijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5076-7435","authenticated-orcid":false,"given":"Vaishali","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay K.","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Mark","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6100-3251","authenticated-orcid":false,"given":"R. Manjunatha","family":"Kini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0389-7450","authenticated-orcid":false,"given":"Mark Y.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,25]]},"reference":[{"key":"27275_CR1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1136\/heart.83.3.361","volume":"83","author":"MJ Davies","year":"2000","unstructured":"Davies, M. J. The pathophysiology of acute coronary syndromes. Heart 83, 361\u2013366 (2000).","journal-title":"Heart"},{"key":"27275_CR2","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1161\/CIRCULATIONAHA.106.675934","volume":"115","author":"TF Luscher","year":"2007","unstructured":"Luscher, T. F. et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115, 1051\u20131058 (2007).","journal-title":"Circulation"},{"key":"27275_CR3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrcardio.2017.18","volume":"14","author":"F Franchi","year":"2017","unstructured":"Franchi, F., Rollini, F. & Angiolillo, D. J. Antithrombotic therapy for patients with STEMI undergoing primary PCI. Nat. Rev. Cardiol. 14, 361\u2013379 (2017).","journal-title":"Nat. Rev. Cardiol."},{"key":"27275_CR4","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.jacc.2009.03.083","volume":"54","author":"MP Bonaca","year":"2009","unstructured":"Bonaca, M. P. et al. Antithrombotics in acute coronary syndromes. J. Am. Coll. Cardiol. 54, 969\u2013984 (2009).","journal-title":"J. Am. Coll. Cardiol."},{"key":"27275_CR5","doi-asserted-by":"publisher","first-page":"E1034","DOI":"10.21037\/jtd.2016.08.79","volume":"8","author":"WB Hillegass","year":"2016","unstructured":"Hillegass, W. B. & Bradford, G. S. Risk guided use of the direct thrombin inhibitor bivalirudin: insights from recent trials and analyses. J. Thorac. Dis. 8, E1034\u2013E1040 (2016).","journal-title":"J. Thorac. Dis."},{"key":"27275_CR6","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/eurheartj\/ehw031","volume":"37","author":"P Widimsky","year":"2016","unstructured":"Widimsky, P. Is bivalirudin just an expensive heparin? Eur. Heart J. 37, 1321\u20131324 (2016).","journal-title":"Eur. Heart J."},{"key":"27275_CR7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41573-020-0061-0","volume":"19","author":"N Mackman","year":"2020","unstructured":"Mackman, N., Bergmeier, W., Stouffer, G. A. & Weitz, J. I. Therapeutic strategies for thrombosis: new targets and approaches. Nat. Rev. Drug Discov. 19, 333\u2013352 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"27275_CR8","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1001\/jama.298.21.2497","volume":"298","author":"GW Stone","year":"2007","unstructured":"Stone, G. W. et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. J. Am. Med. Assoc. 298, 2497\u20132506 (2007).","journal-title":"J. Am. Med. Assoc."},{"key":"27275_CR9","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","volume":"358","author":"GW Stone","year":"2008","unstructured":"Stone, G. W. et al. Bivalirudin during primary PCI in acute myocardial infarction. N. Engl. J. Med. 358, 2218\u20132230 (2008).","journal-title":"N. Engl. J. Med."},{"key":"27275_CR10","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1001\/jama.289.7.853","volume":"289","author":"AM Lincoff","year":"2003","unstructured":"Lincoff, A. M. et al. Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. J. Am. Med. Assoc. 289, 853\u2013863 (2003).","journal-title":"J. Am. Med. Assoc."},{"key":"27275_CR11","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(14)60924-7","volume":"384","author":"A Shahzad","year":"2014","unstructured":"Shahzad, A. et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 384, 1849\u20131858 (2014).","journal-title":"Lancet"},{"key":"27275_CR12","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1001\/jama.2015.2323","volume":"313","author":"Y Han","year":"2015","unstructured":"Han, Y. et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. J. Am. Med. Assoc. 313, 1336\u20131346 (2015).","journal-title":"J. Am. Med. Assoc."},{"key":"27275_CR13","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.jacc.2018.01.033","volume":"71","author":"G Gargiulo","year":"2018","unstructured":"Gargiulo, G. et al. Bivalirudin or heparin in patients undergoing invasive management of acute coronary syndromes. J. Am. Coll. Cardiol. 71, 1231\u20131242 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"27275_CR14","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa1706443","volume":"377","author":"D Erlinge","year":"2017","unstructured":"Erlinge, D. et al. Bivalirudin versus heparin monotherapy in myocardial infarction. N. Engl. J. Med. 377, 1132\u20131142 (2017).","journal-title":"N. Engl. J. Med."},{"key":"27275_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","volume":"40","author":"FJ Neumann","year":"2019","unstructured":"Neumann, F. J. et al. 2018 ESC\/EACTS guidelines on myocardial revascularization. Eur. Heart J. 40, 87\u2013165 (2019).","journal-title":"Eur. Heart J."},{"key":"27275_CR16","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/j.jcin.2016.09.020","volume":"9","author":"EA Secemsky","year":"2016","unstructured":"Secemsky, E. A. et al. Use and effectiveness of bivalirudin versus unfractionated heparin for percutaneous coronary intervention among patients with ST-segment elevation myocardial infarction in the United States. JACC Cardiovasc Inter. 9, 2376\u20132386 (2016).","journal-title":"JACC Cardiovasc Inter."},{"key":"27275_CR17","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jacc.2019.02.080","volume":"74","author":"FWA Verheugt","year":"2019","unstructured":"Verheugt, F. W. A., Ten Berg, J. M., Storey, R. F., Cuisset, T. & Granger, C. B. Antithrombotics: from aspirin to DOACs in coronary artery disease and atrial fibrillation (Part 3\/5). J. Am. Coll. Cardiol. 74, 699\u2013711 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"27275_CR18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.jacc.2020.09.011","volume":"77","author":"DJ Kumbhani","year":"2021","unstructured":"Kumbhani, D. J. et al. 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease. J. Am. Coll. Cardiol. 77, 629\u2013658 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"27275_CR19","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1160\/TH09-04-0221","volume":"102","author":"CY Koh","year":"2009","unstructured":"Koh, C. Y. & Kini, R. M. Molecular diversity of anticoagulants from haematophagous animals. Thromb. Haemost. 102, 437\u2013453 (2009).","journal-title":"Thromb. Haemost."},{"key":"27275_CR20","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1126\/science.2374926","volume":"249","author":"TJ Rydel","year":"1990","unstructured":"Rydel, T. J. et al. The structure of a complex of recombinant hirudin and human alpha-thrombin. Science 249, 277\u2013280 (1990).","journal-title":"Science"},{"key":"27275_CR21","doi-asserted-by":"publisher","first-page":"E3649","DOI":"10.1073\/pnas.1211614109","volume":"109","author":"AC Figueiredo","year":"2012","unstructured":"Figueiredo, A. C. et al. Unique thrombin inhibition mechanism by anophelin, an anticoagulant from the malaria vector. Proc. Natl Acad. Sci. USA 109, E3649\u2013E3658 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"27275_CR22","doi-asserted-by":"publisher","first-page":"16678","DOI":"10.1021\/bi991231p","volume":"38","author":"IM Francischetti","year":"1999","unstructured":"Francischetti, I. M., Valenzuela, J. G. & Ribeiro, J. M. Anophelin: kinetics and mechanism of thrombin inhibition. Biochemistry 38, 16678\u201316685 (1999).","journal-title":"Biochemistry"},{"key":"27275_CR23","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1046\/j.1432-1033.2003.03560.x","volume":"270","author":"S Iwanaga","year":"2003","unstructured":"Iwanaga, S. et al. Identification and characterization of novel salivary thrombin inhibitors from the ixodidae tick, Haemaphysalis longicornis. Eur. J. Biochem. 270, 1926\u20131934 (2003).","journal-title":"Eur. J. Biochem."},{"key":"27275_CR24","doi-asserted-by":"publisher","first-page":"475","DOI":"10.4269\/ajtmh.1996.54.475","volume":"54","author":"M Cappello","year":"1996","unstructured":"Cappello, M. et al. Isolation and characterization of the tsetse thrombin inhibitor: a potent antithrombotic peptide from the saliva of Glossina morsitans morsitans. Am. J. Trop. Med Hyg. 54, 475\u2013480 (1996).","journal-title":"Am. J. Trop. Med Hyg."},{"key":"27275_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.chembiol.2020.10.002","volume":"28","author":"BM Calisto","year":"2021","unstructured":"Calisto, B. M. et al. Sulfotyrosine-mediated recognition of human thrombin by a Tsetse fly anticoagulant mimics physiological substrates. Cell Chem. Biol. 28, 26\u201333 e28 (2021).","journal-title":"Cell Chem. Biol."},{"key":"27275_CR26","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nchem.2744","volume":"9","author":"RE Thompson","year":"2017","unstructured":"Thompson, R. E. et al. Tyrosine sulfation modulates activity of tick-derived thrombin inhibitors. Nat. Chem. 9, 909\u2013917 (2017).","journal-title":"Nat. Chem."},{"key":"27275_CR27","doi-asserted-by":"publisher","first-page":"5348","DOI":"10.1002\/anie.202015127","volume":"60","author":"SM Agten","year":"2021","unstructured":"Agten, S. M. et al. Potent trivalent inhibitors of thrombin through hybridization of salivary sulfopeptides from hematophagous arthropods. Angew. Chem. Int. Ed. Engl. 60, 5348\u20135356 (2021).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"27275_CR28","doi-asserted-by":"publisher","first-page":"7095","DOI":"10.1021\/bi00482a021","volume":"29","author":"JM Maraganore","year":"1990","unstructured":"Maraganore, J. M., Bourdon, P., Jablonski, J., Ramachandran, K. L. & Fenton, J. W. 2nd Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 29, 7095\u20137101 (1990).","journal-title":"Biochemistry"},{"key":"27275_CR29","doi-asserted-by":"publisher","first-page":"29101","DOI":"10.1074\/jbc.M705600200","volume":"282","author":"CY Koh","year":"2007","unstructured":"Koh, C. Y. et al. Variegin, a novel fast and tight binding thrombin inhibitor from the tropical bont tick. J. Biol. Chem. 282, 29101\u201329113 (2007).","journal-title":"J. Biol. Chem."},{"key":"27275_CR30","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1096\/fj.201601216R","volume":"31","author":"JK Iyer","year":"2017","unstructured":"Iyer, J. K. et al. Avathrin: a novel thrombin inhibitor derived from a multicopy precursor in the salivary glands of the ixodid tick, Amblyomma variegatum. FASEB J. 31, 2981\u20132995 (2017).","journal-title":"FASEB J."},{"key":"27275_CR31","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1002\/cbic.200900371","volume":"10","author":"CY Koh","year":"2009","unstructured":"Koh, C. Y., Kazimirova, M., Nuttall, P. A. & Kini, R. M. Noncompetitive inhibitor of thrombin. Chembiochem 10, 2155\u20132158 (2009).","journal-title":"Chembiochem"},{"key":"27275_CR32","doi-asserted-by":"publisher","first-page":"e26367","DOI":"10.1371\/journal.pone.0026367","volume":"6","author":"CY Koh","year":"2011","unstructured":"Koh, C. Y. et al. Crystal structure of thrombin in complex with S-variegin: insights of a novel mechanism of inhibition and design of tunable thrombin inhibitors. PLoS ONE 6, e26367 (2011).","journal-title":"PLoS ONE"},{"key":"27275_CR33","doi-asserted-by":"publisher","first-page":"693","DOI":"10.4155\/bio-2017-0006","volume":"9","author":"N Shih","year":"2017","unstructured":"Shih, N. et al. Development of bioanalytical assays for variegin, a peptide-based bivalent direct thrombin inhibitor. Bioanalysis 9, 693\u2013705 (2017).","journal-title":"Bioanalysis"},{"key":"27275_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-12-136","volume":"12","author":"JM Ribeiro","year":"2011","unstructured":"Ribeiro, J. M., Anderson, J. M., Manoukis, N. C., Meng, Z. & Francischetti, I. M. A further insight into the sialome of the tropical bont tick, Amblyomma variegatum. BMC Genomics 12, 136 (2011).","journal-title":"BMC Genomics"},{"key":"27275_CR35","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1042\/bj2830737","volume":"283","author":"JI Witting","year":"1992","unstructured":"Witting, J. I., Bourdon, P., Brezniak, D. V., Maraganore, J. M. & Fenton, J. W. 2nd Thrombin-specific inhibition by and slow cleavage of hirulog-1. Biochem J. 283, 737\u2013743 (1992).","journal-title":"Biochem J."},{"key":"27275_CR36","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12959-019-0201-0","volume":"17","author":"K Suzuki","year":"2019","unstructured":"Suzuki, K. et al. Usefulness of the APTT waveform for the diagnosis of DIC and prediction of the outcome or bleeding risk. Thromb. J. 17, 12 (2019).","journal-title":"Thromb. J."},{"key":"27275_CR37","doi-asserted-by":"publisher","first-page":"107602962091202","DOI":"10.1177\/1076029620912027","volume":"26","author":"H Wada","year":"2020","unstructured":"Wada, H., Matsumoto, T., Ohishi, K., Shiraki, K. & Shimaoka, M. Update on the clot waveform analysis. Clin. Appl Thromb. Hemost. 26, 1076029620912027 (2020).","journal-title":"Clin. Appl Thromb. Hemost."},{"key":"27275_CR38","first-page":"S48","volume":"34 Suppl 1","author":"T Siegemund","year":"2014","unstructured":"Siegemund, T., Scholz, U., Schobess, R. & Siegemund, A. Clot waveform analysis in patients with haemophilia A. Hamostaseologie 34 Suppl 1, S48\u2013S52 (2014).","journal-title":"Hamostaseologie"},{"key":"27275_CR39","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1111\/jth.13766","volume":"15","author":"C Ay","year":"2017","unstructured":"Ay, C., Hisada, Y., Cooley, B. C. & Mackman, N. Factor XI-deficient mice exhibit increased bleeding after injury to the saphenous vein. J. Thromb. Haemost. 15, 1829\u20131833 (2017).","journal-title":"J. Thromb. Haemost."},{"key":"27275_CR40","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/j.thromres.2014.03.003","volume":"133 Suppl 1","author":"DM Monroe","year":"2014","unstructured":"Monroe, D. M. & Hoffman, M. A mouse bleeding model to study oral anticoagulants. Thromb. Res. 133 Suppl 1, S6\u2013S8 (2014).","journal-title":"Thromb. Res."},{"key":"27275_CR41","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1111\/jth.12033","volume":"10","author":"EM Becker","year":"2012","unstructured":"Becker, E. M. et al. Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis. J. Thromb. Haemost. 10, 2470\u20132480 (2012).","journal-title":"J. Thromb. Haemost."},{"key":"27275_CR42","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1161\/01.CIR.0000142296.19558.99","volume":"110","author":"G Vilahur","year":"2004","unstructured":"Vilahur, G., Segales, E., Salas, E. & Badimon, L. Effects of a novel platelet nitric oxide donor (LA816), aspirin, clopidogrel, and combined therapy in inhibiting flow- and lesion-dependent thrombosis in the porcine ex vivo model. Circulation 110, 1686\u20131693 (2004).","journal-title":"Circulation"},{"key":"27275_CR43","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/978-1-4939-8597-5_12","volume":"1816","author":"MU Zafar","year":"2018","unstructured":"Zafar, M. U., Santos-Gallego, C. G., Badimon, L. & Badimon, J. J. Badimon perfusion chamber: an ex vivo model of thrombosis. Methods Mol. Biol. 1816, 161\u2013171 (2018).","journal-title":"Methods Mol. Biol."},{"key":"27275_CR44","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/cvr\/cvy227","volume":"115","author":"SJ Wilson","year":"2019","unstructured":"Wilson, S. J. et al. Exosite 1 thrombin inhibition with JNJ-64179375 inhibits thrombus formation in a human translational model of thrombosis. Cardiovasc Res. 115, 669\u2013677 (2019).","journal-title":"Cardiovasc Res."},{"key":"27275_CR45","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1161\/ATVBAHA.117.310104","volume":"38","author":"SJ Wilson","year":"2018","unstructured":"Wilson, S. J. et al. PAR4 (Protease-activated receptor 4) antagonism with BMS-986120 inhibits human ex vivo thrombus formation. Arterioscler Thromb. Vasc. Biol. 38, 448\u2013456 (2018).","journal-title":"Arterioscler Thromb. Vasc. Biol."},{"key":"27275_CR46","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nrd3845","volume":"11","author":"J Bowes","year":"2012","unstructured":"Bowes, J. et al. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat. Rev. Drug Discov. 11, 909\u2013922 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"27275_CR47","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1161\/01.CIR.103.24.2994","volume":"103","author":"J Hirsh","year":"2001","unstructured":"Hirsh, J., Anand, S. S., Halperin, J. L. & Fuster, V., American Heart A. Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. Circulation 103, 2994\u20133018 (2001).","journal-title":"Circulation"},{"key":"27275_CR48","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S0140-6736(14)61216-2","volume":"384","author":"MA Cavender","year":"2014","unstructured":"Cavender, M. A. & Sabatine, M. S. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials. Lancet 384, 599\u2013606 (2014).","journal-title":"Lancet"},{"key":"27275_CR49","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1507854","volume":"373","author":"M Valgimigli","year":"2015","unstructured":"Valgimigli, M. et al. Bivalirudin or unfractionated heparin in acute coronary syndromes. N. Engl. J. Med. 373, 997\u20131009 (2015).","journal-title":"N. Engl. J. Med."},{"key":"27275_CR50","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jcin.2014.11.002","volume":"8","author":"P Clemmensen","year":"2015","unstructured":"Clemmensen, P. et al. Acute stent thrombosis after primary percutaneous coronary intervention: insights from the EUROMAX trial (European Ambulance Acute Coronary Syndrome Angiography). JACC Cardiovasc Inter. 8, 214\u2013220 (2015).","journal-title":"JACC Cardiovasc Inter."},{"key":"27275_CR51","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1161\/CIRCINTERVENTIONS.110.959098","volume":"4","author":"C Kimmelstiel","year":"2011","unstructured":"Kimmelstiel, C. et al. Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention. Circ. Cardiovasc Inter. 4, 171\u2013179 (2011).","journal-title":"Circ. Cardiovasc Inter."},{"key":"27275_CR52","doi-asserted-by":"crossref","unstructured":"Panova-Noeva, M., van der Meijden, P. E. J. & Ten Cate, H. Clinical applications, pitfalls, and uncertainties of thrombin generation in the presence of platelets. J. Clin. Med. 9, 92 (2019).","DOI":"10.3390\/jcm9010092"},{"key":"27275_CR53","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1161\/CIRCRESAHA.117.312012","volume":"121","author":"JD McFadyen","year":"2017","unstructured":"McFadyen, J. D. & Peter, K. Novel antithrombotic drugs on the horizon: the ultimate promise to prevent clotting while avoiding bleeding. Circ. Res. 121, 1133\u20131135 (2017).","journal-title":"Circ. Res."},{"key":"27275_CR54","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1080\/09537104.2020.1719056","volume":"31","author":"BM Mohammed","year":"2020","unstructured":"Mohammed, B. M., Monroe, D. M. & Gailani, D. Mouse models of hemostasis. Platelets 31, 417\u2013422 (2020).","journal-title":"Platelets"},{"key":"27275_CR55","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/jps.2600680519","volume":"68","author":"HJ Rodriguez","year":"1979","unstructured":"Rodriguez, H. J. & Vanderwielen, A. J. Molecular weight determination of commercial heparin sodium USP and its sterile solutions. J. Pharm. Sci. 68, 588\u2013591 (1979).","journal-title":"J. Pharm. Sci."},{"key":"27275_CR56","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0003-2697(02)00428-1","volume":"312","author":"X Guo","year":"2003","unstructured":"Guo, X. et al. Determination of molecular weight of heparin by size exclusion chromatography with universal calibration. Anal. Biochem. 312, 33\u201339 (2003).","journal-title":"Anal. Biochem."},{"key":"27275_CR57","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1111\/jth.12287","volume":"11","author":"M Shima","year":"2013","unstructured":"Shima, M., Thachil, J., Nair, S. C. & Srivastava, A., Scientific, Standardization C. Towards standardization of clot waveform analysis and recommendations for its clinical applications. J. Thromb. Haemost. 11, 1417\u20131420 (2013).","journal-title":"J. Thromb. Haemost."},{"key":"27275_CR58","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.thromres.2010.04.005","volume":"126","author":"N Konishi","year":"2010","unstructured":"Konishi, N., Hiroe, K. & Kawamura, M. Synergistic effect of a factor Xa inhibitor, TAK-442, and antiplatelet agents on whole blood coagulation and arterial thrombosis in rats. Thromb. Res. 126, 124\u2013129 (2010).","journal-title":"Thromb. Res."},{"key":"27275_CR59","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1160\/TH09-10-0744","volume":"104","author":"S Pehrsson","year":"2010","unstructured":"Pehrsson, S., Johansson, K., Kjaer, M. & Elg, M. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats. Thromb. Haemost. 104, 1242\u20131249 (2010).","journal-title":"Thromb. Haemost."},{"key":"27275_CR60","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/j.1365-2516.2012.02780.x","volume":"18","author":"AE Pastoft","year":"2012","unstructured":"Pastoft, A. E. et al. A sensitive venous bleeding model in haemophilia A mice: effects of two recombinant FVIII products (N8 and Advate((R))). Haemophilia 18, 782\u2013788 (2012).","journal-title":"Haemophilia"},{"key":"27275_CR61","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1016\/j.jacc.2011.08.007","volume":"58","author":"GN Levine","year":"2011","unstructured":"Levine, G. N. et al. 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention. J. Am. Coll. Cardiol. 58, e44\u2013e122 (2011).","journal-title":"J. Am. Coll. Cardiol."},{"key":"27275_CR62","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1053\/euhj.1998.1042","volume":"19","author":"RR Makkar","year":"1998","unstructured":"Makkar, R. R. et al. Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis. Eur. Heart J. 19, 1538\u20131546 (1998).","journal-title":"Eur. Heart J."},{"key":"27275_CR63","doi-asserted-by":"publisher","first-page":"e0191315","DOI":"10.1371\/journal.pone.0191315","volume":"13","author":"V Verma","year":"2018","unstructured":"Verma, V., Kaur, C., Grover, P., Gupta, A. & Chaudhary, V. K. Biotin-tagged proteins: reagents for efficient ELISA-based serodiagnosis and phage display-based affinity selection. PLoS ONE 13, e0191315 (2018).","journal-title":"PLoS ONE"},{"key":"27275_CR64","unstructured":"Chaudhary, V. K., Gupta, A. & Verma, V. An antibody fragment library, and uses thereof; PCT publication no. WO2019106694A1 (2019)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27275-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27275-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27275-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T22:11:05Z","timestamp":1675894265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27275-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,25]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["27275"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-27275-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,25]]},"assertion":[{"value":"25 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Part of the work related to the peptides as thrombin inhibitors was included in the patent application with C.Y.K., J.K.I. and R.M.K. among the inventors (WO2016204696A1 Novel thrombin inhibitors). Antibodies tested as reversal agents for ultravariegin were included in another patent application with C.Y.K., V.V., A.G., V.K.C., R.M.K. and M.Y.C. among the inventors (application in progress). The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6912"}}